Company: ABUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001447028-25-000115
Chunk: 93

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 2
Chunk 93
---
 3,973 Change in deferred license revenue(10,434)(757)Net change in other operating items(2,537)656 Net cash used in operating activities(29,140)(33,799)Net cash provided by investing activities26,960 21,523 Issuance of common shares pursuant to the Open Market Sale Agreement— 44,124 Cash provided by other financing activities3,237 4,676 Net cash provided by financing activities3,237 48,800 Effect of foreign exchange rate changes on cash and cash equivalents25 (21)Increase in cash and cash equivalents1,082 36,503 Cash and cash equivalents, beginning of period36,330 26,285 Cash and cash equivalents, end of period$37,412 $62,788 

Since our incorporation, we have financed our operations through sales of equity, debt, revenues from research and development collaborations and licenses with corporate partners, royalty monetization, interest income on funds available for investment, and government contracts, grants and tax credits.

For the six months ended June 30, 2025, $29.1 million of cash was used in operating activities compared to $33.8 million used in operating activities for the six months ended June 30, 2024, a decrease of $4.7 million. The decrease was due primarily to our decisions to cease all discovery efforts, discontinue our IM-PROVE III clinical trial, and decrease our workforce to further streamline the organization to focus our efforts on advancing the clinical development of imdusiran and AB-101.  

For the six months ended June 30, 2025, net cash provided by investing activities was $27.0 million, resulting primarily from maturities of investments in marketable securities of $90.2 million, partially offset by additional investments in marketable securities of $63.2 million. For the six months ended June 30, 2024, net cash provided by investing activities was $21.5 million, which resulted primarily from maturities of investments in marketable securities of $79.6 million, partially offset by additional investments in marketable securities of $58.0 million.

For the six months ended June 30, 2025, net cash provided by financing activities was $3.2 million, which was primarily related to $3.1 million in proceeds from the issuance of common shares pursuant to the exercise of stock options. For the six months ended